Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.

Singh ZN, Jethava Y, Post GR, Alapat D, Sawyer J, Waheed S, Nair B, Usmani SZ, Bailey C, Petty N, Van Rhee F, Barlogie B; Clin Case Rep. 2015-03-01.

https://www.ncbi.nlm.nih.gov/pubmed/25415285

Szmania, S.,Lapteva, N.,Garg, T.,Greenway, A.,Lingo, J.,Nair, B.,Stone, K.,Woods, E.,Khan, J.,Stivers, J.,Panozzo, S.,Campana, D.,Bellamy, W. T.,Robbins, M.,Epstein, J...; J. Immunother.. 2014 Nov 22.

High-risk myeloma: when to transplant-or not.

Eicher DM, Lonial S, Cavallo F, Palumbo A, Nair B, Waheed S, Hofmeister C, Rogers HJ; Semin. Oncol.. 2014-02-01.

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

Dhodapkar, M. V.,Sexton, R.,Waheed, S.,Usmani, S.,Papanikolaou, X.,Nair, B.,Perry, N.,Shaughnessy, J. D.,Hoering, A.,Crowley, J.,Orlowski, R. Z.,Barlogie, B.; Blood. 2013 Oct 23.

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.

Waheed, S.,Mitchell, A.,Usmani, S.,Epstein, J.,Yaccoby, S.,Nair, B.,van Hemert, R.,Angtuaco, E.,Brown, T.,Bartel, T.,McDonald, J.,Anaissie, E.,van Rhee, F.,Crowley, J....; Haematologica. 2013 Jan.

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols.

Usmani, S. Z., Nair, B., Qu, P., Hansen, E., Zhang, Q., Petty, N., Waheed, S., Shaughnessy, J. D., Alsayed, Y., Heuck, C. J., van Rhee, F., Milner, T., Hoering, A., Sz...; Leukemia. 2012 Nov.

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.

Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, Greenway AD, Lingo JD, Li X, Yaccoby S, Suva LJ, Storrie B, Tricot G, Campana D, Shaughnessy JD, ...; Haematologica. 2012-09-01.

Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.

Heuck, C., Szymonifka, J., Hansen, E., Shaughnessy, J. D., Usmani, S., Van Rhee, F., Anaissie, E., Nair, B., Waheed, S., Alsayed, Y., Petty, N., Bailey, C., Epstein, J...; Clin Cancer Res. 2012 Oct 1.

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

Usmani, S. Z., Crowley, J., Hoering, A., Mitchell, A., Waheed, S., Nair, B., Alsayed, Y., Vanrhee, F., Barlogie, B.; Leukemia. 2013 Jan.

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.

Usmani, S. Z., Heuck, C., Mitchell, A., Szymonifka, J., Nair, B., Hoering, A., Alsayed, Y., Waheed, S., Haider, S., Restrepo, A., van Rhee, F., Crowley, J., Barlogie, B.; Haematologica. 2012 Nov.

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.

Usmani, S. Z., Sexton, R., Hoering, A., Heuck, C. J., Nair, B., Waheed, S., Alsayed, Y., Chauhan, N., Ahmad, N., Atrash, S., Petty, N., van Rhee, F., Crowley, J., Barl...; Blood. 2012 Aug 23.

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Shaughnessy JD, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, ...; Blood. 2011-09-29.

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.

Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B; Cancer. 2011-03-01.

Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.

Li X, Ling W, Pennisi A, Wang Y, Khan S, Heidaran M, Pal A, Zhang X, He S, Zeitlin A, Abbot S, Faleck H, Hariri R, Shaughnessy JD, van Rhee F, Nair B, Barlogie B, Epst...; Stem Cells. 2011-02-01.

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.

van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD, Hoering A, Crowley J, Barlogie B; Blood. 2010-08-26.

Solitary extramedullary and bone plasmacytomas versus multiple myeloma with extramedullary manifestation.

Nair, B.; Oncology (Williston Park, N.Y.). 2010 Oct 07.

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

Nair, B.,van Rhee, F.,Shaughnessy, J. D.,Anaissie, E.,Szymonifka, J.,Hoering, A.,Alsayed, Y.,Waheed, S.,Crowley, J.,Barlogie, B.; Blood. 2010 Feb 04.

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.

Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, Cartron M, van Rhee F, Nair B, Waheed S, Pineda-Roman M, Alsayed Y, Anaissie E, Shaughnessy JD; Proc. Natl. Acad. Sci. U.S.A.. 2010-04-27.

TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.

Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Epstein J, Crowley J, Barlogie B; Br. J. Haematol.. 2009-11-01.